Senior executives of multinational pharmaceutical companies: Openness + opportunities attract companies to take root in China and deepen cooperation

China News Service, Shanghai, October 26 (Reporter Chen Jing) The ninth China International Import Expo is about to open. "We have attended the CIIE for five consecutive years. What we feel most deeply is the opportunities unleashed by China's continued expansion of high-level opening up and encouragement of medical innovation." Jin Fangqian, global vice president and general manager of China of Gilead Sciences, a world-leading biopharmaceutical company, told reporters on the 26th.

Jin Fangqian said, "We look forward to continuing to take root in China and deepen cooperation with partners such as the government, medical institutions, industry associations, and patient organizations, so that global innovations can reach Chinese patients faster and earlier, and through continued local practice, we can create health value that is accessible and perceptible to patients."

This year, Gilead Sciences will appear at the CIIE for the fifth consecutive year. Since its first participation in the exhibition in 2022, Gilead Sciences has regarded the CIIE as an important bridge connecting global innovation and Chinese patients. Jin Fangqian said: "For Gilead Sciences, the CIIE is not only a window to showcase the world's cutting-edge innovation results, but also an important platform to connect innovation, cooperation and patient needs." In the past five years, from the debut of innovative products in China to the accelerated implementation of domestic approvals, from cooperation signing to solid advancement of projects, the CIIE has witnessed Gilead Sciences' solid steps to continue to deepen its presence in China and fulfill its long-term commitments. It has also witnessed the transformation of innovative results from "exhibits" to clinical practice, and from visions to tangible health benefits for patients.

According to reports, at the 9th China International Import Expo, Gilead Sciences will display its global innovations in the fields of human immunodeficiency virus (HIV) pre-exposure prophylaxis, liver disease, tumors and antifungals at a 500-square-meter booth, as well as the latest progress of a number of innovative therapies from exhibits to clinical practice, benefiting Chinese patients. It will also bring the latest practices of working with multiple partners to promote disease prevention and treatment and benefit patients.

Lenacapavir, the world's first long-acting HIV capsid inhibitor for HIV pre-exposure prophylaxis, and Seladelpar, an innovative treatment for rare diseases, have attracted much attention. The former relies on Hainan Boao Lecheng's "pilot first" policy to achieve access, and has benefited many people with HIV prevention needs, and is expected to provide new assistance to further enrich China's comprehensive HIV prevention and control methods; the latter is used to treat primary biliary cholangitis (PBC) and has been approved for use in the Beijing Tianzhu Rare Disease Drug Guarantee Pilot Zone and Hainan Boao Lecheng, and has been included in the overseas drug catalog by many places.

In the past five years, Gilead Sciences has relied on the CIIE platform to continuously expand its cooperation network and promote a series of cooperations in areas such as disease prevention and treatment, standardized diagnosis and treatment, and patient services, from signing to implementation, and from projects to long-term value. From the recall of hepatitis C patients, to the standardized management of viral hepatitis, to the construction of diagnostic and treatment capabilities for invasive fungal diseases, a series of long-term cooperation is allowing the signings and consensus at the CIIE to go beyond the booth and continue to create value in a broader real medical scenario.

During the 9th China International Import Expo, the Gilead Sciences booth will focus deeply on the health benefits that innovation brings to patients, and will use diverse activities to bring cutting-edge medical innovations closer to the public, allowing more people to understand disease prevention and treatment knowledge and pay attention to real patient needs.